Michael Berelowitz - Kamada Director

KMDA Stock  USD 5.10  0.05  0.99%   

Director

Dr. Michael Berelowitz was appointed Director at Kamada Ltd effective August 4, 2015. Dr. Berelowitz has over 40 years of clinical development and academic research experience, including 5 years of pharmaceutical development experience with Pfizer, Inc. Prior to that, Dr. Berelowitz spent a number of years in academia and has held appointments at the University of Chicago, University of Cincinnati College of Medicine, SUNY at StonyBrook and, most recently, Mount Sinai School of Medicine since 2015.
Age 70
Tenure 9 years
Professional MarksPh.D
Address 2 Holzman Street, Rehovot, Israel, 7670402
Phone972 8 940 6472
Webhttps://www.kamada.com
Berelowitz serves as a biopharmaceuticals consultant. He holds Directorship Oramed Pharmaceuticals, Recro Pharma, Inc. and DIR Technologies. Additionally, Dr. Berelowitz has served on the Board of Directors of the American Diabetes Association, the Endocrine Fellows Foundation, the Clinical Initiatives Committee of the Endocrine Society, Metacure, Ltd., Haptocure, Ltd., and has chaired the Task Force on Research of the New York State Council on Diabetes.Dr. Berelowitz completed his medical degree, residency training in Pathology, Nuclear Medicine and Internal Medicine and fellowship training in Endocrinology and Metabolism at the University of Cape Town.

Kamada Management Efficiency

The company has return on total asset (ROA) of 0.0186 % which means that it generated a profit of $0.0186 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0394 %, meaning that it created $0.0394 on every $100 dollars invested by stockholders. Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.04. The current year's Return On Capital Employed is expected to grow to 0.04. At present, Kamada's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 192.6 M, whereas Non Currrent Assets Other are forecasted to decline to about 480.5 K.
The company currently holds 8.75 M in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest the company is not taking enough advantage from borrowing. Kamada has a current ratio of 2.34, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Kamada until it has trouble settling it off, either with new capital or with free cash flow. So, Kamada's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kamada sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kamada to invest in growth at high rates of return. When we think about Kamada's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Caroline YoungCumberland Pharmaceuticals
N/A
Carol WrennPhibro Animal Health
57
Edward OwensIronwood Pharmaceuticals
71
Sander FlaumEagle Pharmaceuticals
81
Michael BonnerCumberland Pharmaceuticals
N/A
Edward BenzDeciphera Pharmaceuticals LLC
71
Shikha SharmaDr Reddys Laboratories
62
Yvonne GreenstreetPacira Pharmaceuticals
55
Adriana KaraboutisPerrigo Company PLC
58
David HirschCollegium Pharmaceutical
47
Richard EdlinEagle Pharmaceuticals
57
Michael RossDeciphera Pharmaceuticals LLC
68
Gary KunklePerrigo Company PLC
67
Gary CohenPerrigo Company PLC
57
Hans HaslerDr Reddys Laboratories
60
Fred HolubowANI Pharmaceuticals
77
Tracy MarshbanksANI Pharmaceuticals
52
Orlando AshfordPerrigo Company PLC
52
Mark BrooksAlimera Sciences
50
Gary CostleyPrestige Brand Holdings
55
Christopher WalshIronwood Pharmaceuticals
71
It operates in two segments, Proprietary Products and Distribution. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. Kamada operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 355 people. Kamada (KMDA) is traded on NASDAQ Exchange in USA. It is located in 2 Holzman Street, Rehovot, Israel, 7670402 and employs 378 people. Kamada is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Kamada Leadership Team

Elected by the shareholders, the Kamada's board of directors comprises two types of representatives: Kamada inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kamada. The board's role is to monitor Kamada's management team and ensure that shareholders' interests are well served. Kamada's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kamada's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pnina Strauss, VP of Clinical Devel. and IP
Itzhak Krinsky, Director
Boris Gorelik, Vice Programs
Barak Bashari, Sr. VP of Operations
Eran Schenker, Vice President - Medical Director
Tuvia Shoham, Director
Eran Nir, Chief Officer
Hanni Neheman, Vice Sales
Shavit Beladev, Vice Plasma
Michal Stein, Vice President and Medical Director for Immunology
Ariella Raban, VP HR
Shani Dotan, Vice President of Human Resources
Liliana Bar, VP of RandD
Yael Brenner, Vice President - Quality
LLB BA, General VP
Abraham Havron, External Director
Asaf Frumerman, Director
Ruth Wolfson, Sr. VP of Scientific Affairs
Shmuel Rubinstein, Director
Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary Diseases
Jon Knight, Vice Operations
Michael Berelowitz, Director
David Tsur, Co-Founder and Deputy Executive Chairman
Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D
Leon Recanati, Director
Liron Reshef, Vice Resources
Gil Efron, CFO, Principal Accounting Officer and Deputy CEO
Jonathan Hahn, Director
Eran Schenkar, Vice President - Medical Director
Gwen Melincoff, Director
Chaime Orlev, Chief Officer
Michal Ayalon, Vice President - Research & Development
Yifat Esq, Gen Legal
Amir London, Chief Officer
Estery GilozRan, Independent Director
Reuven Behar, Director
Eitan Kyiet, Vice President - Business Development
Ziv Kop, Director

Kamada Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kamada a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Kamada offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kamada's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kamada Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kamada Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kamada. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Kamada Stock refer to our How to Trade Kamada Stock guide.
Note that the Kamada information on this page should be used as a complementary analysis to other Kamada's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Kamada Stock analysis

When running Kamada's price analysis, check to measure Kamada's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kamada is operating at the current time. Most of Kamada's value examination focuses on studying past and present price action to predict the probability of Kamada's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kamada's price. Additionally, you may evaluate how the addition of Kamada to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Global Correlations
Find global opportunities by holding instruments from different markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Equity Valuation
Check real value of public entities based on technical and fundamental data
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Is Kamada's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kamada. If investors know Kamada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kamada listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.227
Earnings Share
0.15
Revenue Per Share
2.919
Quarterly Revenue Growth
(0.20)
Return On Assets
0.0186
The market value of Kamada is measured differently than its book value, which is the value of Kamada that is recorded on the company's balance sheet. Investors also form their own opinion of Kamada's value that differs from its market value or its book value, called intrinsic value, which is Kamada's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kamada's market value can be influenced by many factors that don't directly affect Kamada's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kamada's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kamada is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kamada's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.